Sidi V, Arsos G, Papakonstantinou E, Hatzipantelis E, Fragandrea I, Gombakis N, Koliouskas E
Department of Pediatric Oncology, Hippokration General Hospital of Thessaloniki, and Department of Nuclear Medicine, Aristotle University School of Medicine, Thessaloniki, Greece.
Hippokratia. 2007 Jan;11(1):25-9.
Preclinical and clinical evaluation of amifostine (AMI) administration in conjunction with systemic chemotherapy supports its role as a cytoprotective agent of normal tissues without loss of impairing the antitumour effectiveness of chemotherapeutic agents. Since only a limited number of clinical studies has been performed using AMI in paediatric pts with malignancies we investigated the protective effect of AMI against carboplatin-induced myelotoxicity and nephrotoxicity in a paediatric group of patients.
AMI was administered in 18/28 paediatric patients with reccurent solid tumours along with ICE (ifosfamide, carboplatin, etoposide) chemotherapy. A significant (p<0.05) decrease in GFR was observed in the control group whereas it was maintained at pre-treatment levels in the AMI-treated group. Leukopenia and neutropenia were significantly (p<0.05) less in AMI-group. No protective effect of AMI was shown concerning thrombocytopenia.
AMI was generally well tolerated at the dose of 740 mg/m2. Side effects including nausea, vomiting, hypotension, flushing and rigors were moderate and reversible and the interruption of infusion was never required.
氨磷汀（AMI）与全身化疗联合应用的临床前和临床评估支持其作为正常组织细胞保护剂的作用，同时不降低化疗药物的抗肿瘤效果。由于在患有恶性肿瘤的儿科患者中使用AMI进行的临床研究数量有限，我们研究了AMI对儿科患者中卡铂诱导的骨髓毒性和肾毒性的保护作用。
18/28例患有复发性实体瘤的儿科患者在接受ICE（异环磷酰胺、卡铂、依托泊苷）化疗的同时给予AMI。对照组观察到肾小球滤过率显著（p<0.05）下降，而在AMI治疗组中肾小球滤过率维持在治疗前水平。AMI组的白细胞减少和中性粒细胞减少显著（p<0.05）较少。未显示AMI对血小板减少有保护作用。
740mg/m²剂量的AMI一般耐受性良好。包括恶心、呕吐、低血压、潮红和寒战在内的副作用为中度且可逆，从未需要中断输注。
